Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Homosildenafil is a **synthetic small-molecule phosphodiesterase type 5 inhibitor** and a structural analog of sildenafil and vardenafil. It has been reported to retain PDE5 inhibitory activity at lower potency than sildenafil, but it is **not an approved medicine and is not a legitimate therapeutic development candidate**. Instead, homosildenafil is best known as an **illicit adulterant** found in counterfeit or undeclared sexual enhancement products and dietary supplements, and it is mainly encountered as an **analytical reference standard** for forensic, quality-control, and regulatory testing rather than as a drug in clinical development. Because it may be consumed unknowingly in adulterated products, it presents meaningful safety and public health concerns similar to other undeclared PDE5 inhibitor analogs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on homosildenafil.